Humacyte (HUMA) Non-Current Deffered Revenue (2020 - 2021)

Humacyte (HUMA) posted quarterly Non-Current Deffered Revenue of $162964.0 for Q2 2021, down 3.03% quarter-over-quarter from $168063.0 in Q1 2021.

Humacyte (HUMA) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends

Humacyte (HUMA) has reported Non-Current Deffered Revenue for 2 consecutive years, with $162964.0 the latest figure, recorded in Q2 2021.

In Q2 2021, Non-Current Deffered Revenue changed N/A year-over-year to $162964.0; the TTM figure through Jun 2021 stood at $162964.0 (changed N/A YoY), while the FY2020 annual figure was $2.0 million, changed N/A from the prior year.
Non-Current Deffered Revenue eased to $162964.0 in Q2 2021 per HUMA's latest filing, from $168063.0 in the prior quarter.
Across five years, Non-Current Deffered Revenue topped out at $2.0 million in Q4 2020 and bottomed at $140937.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	220.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	147.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Humacyte	150.77 Mn	150.77 Mn	-825,000.00	-

Download Data